However, the molecular mechanisms by which cancer cells respond to BET inhibition are not well understood.
Targeting BET family proteins has recently emerged as a promising anticancer strategy. Bromodomain and extra-terminal domain (BET) family proteins are epigenetic readers that play a critical role in oncogenesis by controlling the expression of oncogenes such as c-Myc.
